Publications

Found 397 results
2012
Nakaya HI, Pulendran B.  2012.  Systems vaccinology: its promise and challenge for HIV vaccine development.. Curr Opin HIV AIDS. 7(1):24-31.
Walker BD, McMichael A.  2012.  The T-Cell Response to HIV.. Cold Spring Harb Perspect Med.
Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A et al..  2012.  TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.. Nat Immunol. 13(7):691-700.
Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun T-W, Churchill M, Di Mascio M, Katlama C et al..  2012.  Towards an HIV cure: a global scientific strategy.. Nat Rev Immunol. 12(8):607-14.
Vanderford TH, Slichter C, Rogers KA, Lawson BO, Obaede R, Else JG, Villinger F, Bosinger SE, Silvestri G.  2012.  Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.. Blood. 119(24):5750-7.
Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro JM, Sanmiguel A, Seaman MS, Ferrari G et al..  2012.  Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.. Nature. 482(7383):89-93.
Doehle BP, Chang K, Rustagi A, McNevin J, McElrath JM, Gale M.  2012.  Vpu Mediates Depletion of Interferon Regulatory Factor 3 during HIV Infection by a Lysosome-Dependent Mechanism.. J Virol. 86(16):8367-74.
Doehle BP, Chang K, Fleming L, McNevin J, Hladik F, McElrath JM, Gale M.  2012.  Vpu-Deficient HIV Strains Stimulate Innate Immune Signaling Responses in Target Cells.. J Virol. 86(16):8499-506.
2011
Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P, Wang S-K, Ramos A, Chan-Hui P-Y, Moyle M et al..  2011.  Broad neutralization coverage of HIV by multiple highly potent antibodies.. Nature. 477(7365):466-70.
Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, Makhema J, De Gruttola V, Walker BD, Essex M.  2011.  Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection.. AIDS. 25(12):1515-22.
Lingappa JR, Petrovski S, Kahle E, Fellay J, Shianna K, McElrath JM, Thomas KK, Baeten JM, Celum C, Wald A et al..  2011.  Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure.. PLoS One. 6(12):e28632.
Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, Kwong PD, Karlsson Hedestam GB, Wyatt RT.  2011.  Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.. PLoS One. 6(1):e16074.
De Rosa SC, Thomas EP, Bui J, Huang Y, DeCamp AC, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R et al..  2011.  HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.. J Immunol. 187(6):3391-401.
Mörner A, Jansson M, Bunnik EM, Schøller J, Vaughan R, Wang Y, Montefiori DC, Otting N, Bontrop R, Bergmeier LA et al..  2011.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.. J Virol. 85(13):6442-52.
Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, Gnanapragasam PNP, Abadir A, Seaman MS, Nussenzweig MC et al..  2011.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.. Science. 334(6060):1289-93.
Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, Carlson JM, Heckerman D, Wang B, Losina E, Leshwedi M et al..  2011.  Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.. J Virol. 85(8):3996-4006.
Radebe M, Nair K, Chonco F, Bishop K, Wright JK, van der Stok M, Bassett IV, Mncube Z, Altfeld M, Walker BD et al..  2011.  Limited immunogenicity of HIV CD8+ T-cell epitopes in acute Clade C virus infection.. J Infect Dis. 204(5):768-76.
Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE et al..  2011.  Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.. J Virol. 85(17):8954-67.
Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TYK, Velinzon K, Seaman MS, Nussenzweig MC.  2011.  Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.. PLoS One. 6(9):e24078.
Walker BD, Ahmed R, Plotkin S.  2011.  Moving ahead an HIV vaccine: use both arms to beat HIV.. Nat Med. 17(10):1194-5.
Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, Wang S-K, Stanfield RL, Julien J-P, Ramos A, Crispin M et al..  2011.  A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.. Science. 334(6059):1097-103.
Bhanich Supapol W, Remis RS, Raboud J, Millson M, Tappero JW, Kaul R, Kulkarni P, McConnell MS, Mock PA, McNicholl JM et al..  2011.  Prevalence and correlates of GB virus C infection in HIV-infected and HIV-uninfected pregnant women in Bangkok, Thailand.. J Med Virol. 83(1):33-44.
Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, Gautam R, Shingai M, Pejchal R, Ramos A, Simek MD et al..  2011.  Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.. Proc Natl Acad Sci U S A. 108(50):20125-9.
Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK, Pietzsch J, Fenyo D, Abadir A, Velinzon K et al..  2011.  Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.. Science. 333(6049):1633-7.
McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R, Louder R, Pejchal R, Sastry M, Dai K et al..  2011.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.. Nature. 480(7377):336-43.

Pages